90
Participants
Start Date
October 13, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2026
Aglatimagene besadenovec
Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
NYU Langone Health, New York
University of Pennsylvania, Philadelphia
University of Maryland, Baltimore, Baltimore
Hunter Holmes McGuire VA Medical Center, Richmond
Virginia Commonwealth University, Richmond
Vanderbilt University Medical Center, Nashville
The Ohio State University Wexner Medical Center, Columbus
Mayo Clinic, Rochester
University of Chicago, Chicago
The University of Texas MD Anderson Cancer Center, Houston
University of Utah, Salt Lake City
Mayo Clinic Hospital, Phoenix
UConn Health, Farmington
Yale University, Yale Cancer Center, New Haven
Lead Sponsor
NYU Langone Health
OTHER
Candel Therapeutics, Inc.
INDUSTRY